OLD National Bancorp IN Purchases 389 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

OLD National Bancorp IN grew its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTHFree Report) by 15.5% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,893 shares of the medical equipment provider’s stock after buying an additional 389 shares during the quarter. OLD National Bancorp IN’s holdings in Lantheus were worth $201,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Covestor Ltd lifted its holdings in shares of Lantheus by 102.5% during the 2nd quarter. Covestor Ltd now owns 324 shares of the medical equipment provider’s stock valued at $27,000 after buying an additional 164 shares during the period. Parkside Financial Bank & Trust lifted its holdings in shares of Lantheus by 60.2% during the 2nd quarter. Parkside Financial Bank & Trust now owns 426 shares of the medical equipment provider’s stock valued at $36,000 after buying an additional 160 shares during the period. First Horizon Advisors Inc. lifted its holdings in shares of Lantheus by 97.0% during the 3rd quarter. First Horizon Advisors Inc. now owns 457 shares of the medical equipment provider’s stock valued at $32,000 after buying an additional 225 shares during the period. Quadrant Capital Group LLC increased its stake in shares of Lantheus by 115.7% in the 2nd quarter. Quadrant Capital Group LLC now owns 496 shares of the medical equipment provider’s stock worth $42,000 after purchasing an additional 266 shares in the last quarter. Finally, Coppell Advisory Solutions LLC purchased a new stake in shares of Lantheus in the 2nd quarter worth $46,000. 99.06% of the stock is owned by institutional investors.

Insider Activity at Lantheus

In related news, Director Mary Anne Heino sold 93,863 shares of the stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $65.31, for a total value of $6,130,192.53. Following the completion of the transaction, the director now owns 251,643 shares of the company’s stock, valued at approximately $16,434,804.33. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other Lantheus news, major shareholder Lantheus Alpha Therapy, Llc bought 60,431,039 shares of the company’s stock in a transaction on Wednesday, March 6th. The stock was acquired at an average price of $0.95 per share, for a total transaction of $57,409,487.05. Following the completion of the transaction, the insider now directly owns 116,773,394 shares of the company’s stock, valued at $110,934,724.30. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Mary Anne Heino sold 93,863 shares of the business’s stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $65.31, for a total value of $6,130,192.53. Following the transaction, the director now owns 251,643 shares of the company’s stock, valued at approximately $16,434,804.33. The disclosure for this sale can be found here. In the last quarter, insiders sold 94,545 shares of company stock valued at $6,168,153. Insiders own 1.50% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the company. Brookline Capital Management assumed coverage on Lantheus in a research note on Thursday, November 30th. They issued a “buy” rating and a $100.00 price objective for the company. TheStreet lowered Lantheus from a “b-” rating to a “c” rating in a research note on Monday, December 18th. William Blair lowered Lantheus from an “outperform” rating to a “market perform” rating in a research note on Monday, December 18th. StockNews.com upgraded Lantheus from a “hold” rating to a “buy” rating in a research note on Saturday, January 13th. Finally, JMP Securities reiterated a “market outperform” rating and issued a $100.00 price target on shares of Lantheus in a research note on Friday, February 23rd. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $104.14.

Get Our Latest Stock Report on LNTH

Lantheus Trading Up 0.3 %

Shares of Lantheus stock opened at $59.83 on Friday. The company has a quick ratio of 5.45, a current ratio of 5.80 and a debt-to-equity ratio of 0.69. Lantheus Holdings, Inc. has a twelve month low of $50.20 and a twelve month high of $100.85. The business has a 50-day moving average price of $58.45 and a 200-day moving average price of $63.96. The firm has a market cap of $4.10 billion, a price-to-earnings ratio of 12.89 and a beta of 0.55.

About Lantheus

(Free Report)

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.

Recommended Stories

Want to see what other hedge funds are holding LNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lantheus Holdings, Inc. (NASDAQ:LNTHFree Report).

Institutional Ownership by Quarter for Lantheus (NASDAQ:LNTH)

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.